Professor of Pharmaceutical Sciences at the University of California, San Francisco, where he has been on the faculty since 1980. He is Program Director of the new NIH-funded graduate program in Pharmaceutical Sciences and Pharmacogenomics. He obtained his Ph.D. in Biochemistry from SUNY/Buffalo. He was a postdoctoral fellow with Demetri Papahadjopoulos at the Roswell Cancer Institute. He received many awards. The principle focus of his research group is to exploit biochemical, biophysical and physiological principles to devise novel drug carriers composed of polymers, peptides or lipids. He has published over 140 manuscripts and received 23 patents. Pr. Szoka is a founder of Sequus Pharmaceuticals (Johnson & Johnson) that introduced sterically stabilized liposomes for anti-cancer drug delivery ( DoxilT) and of Valentis, a company developing gene therapies-based drugs to treat cancer and genetic diseases
Pharmaceutical Sciences